Pompe disease - Xconomy

by in

Entry	Author	Date	Location
Henri Termeer on Startups, Drug Prices, Getting Older (Part 2)	Luke Timmerman	05/14/13	National
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments	Arlene Weintraub	01/11/12	New York
BioMarin Buys ZyStor For $115M	Luke Timmerman	08/18/10	San Francisco
FDA Approves Genzyme Pompe Drug, Vertex Hepatitis C Drug Trial Succeeds, Thermo Fisher Acquires Fermentas, & More Boston-Area Life Sciences News	Erin Kutz	05/28/10	Boston
Genzyme Gets FDA Nod for Pompe Drug	Ryan McBride	05/25/10	Boston
FDA to Rule on Genzyme Drug in Six Months	Ryan McBride	01/21/10	Boston
FDA Shoots Down Genzyme’s Latest Bid for Pompe Drug Approval	Ryan McBride	11/16/09	Boston
Genzyme Fails to Win FDA Approval for Large-Scale Production of Pompe Drug	Luke Timmerman	03/02/09	Boston
Genzyme Nabs Two Key Regulatory Approvals, Expected to Trigger Revenue Growth	Ryan McBride	02/26/09	Boston
FDA Plans To Clear Genzyme’s Myozyme Made at Large Scale	Luke Timmerman	11/17/08	Boston
FDA Panel Favors Genzyme’s Myozyme	Ryan McBride	10/22/08	Boston
Genzyme Expects FDA Review of Myozyme Factory by Thanksgiving Weekend	Luke Timmerman	09/23/08	Boston
Page 1 of 1

Xconomy National